Shanghai startup NK CellTech closed a Series A round to raise over RMB100 million ($15 million) to help it advance its NK cell therapy pipeline and R&D. More news from Triastek.
Vaccine developer Shanghai Rongsheng Biotech filed for an IPO with Shanghai's STAR board to raise over RMB1.25 billion ($186.7 million) with Essence Securities as its sponsor. More news from Winsunny, Allist, Akeso.
Backed by CICC, Beijing Luzhu Biotechnology filed for an IPO in Hong Kong with plans to spend 40% of the proceeds on LZ901, a herpes zoster vaccine candidate. More news from Visum, Henlius, GenFleet, Bayer, Hengrui.
Amgen announced a partnership with Fosun Pharma to commercialize Otezla and Parsabiv in mainland China. More news from BMS, Luzhu, LaNova, ImmuneOnco, Clover.
Westlake Therapeutics, an Hangzhou-based biotech company that focuses on red blood cell (RBC)-based therapy, has closed its Series A+ funding led by Efung Capital to raise over RMB100 million ($15 million). More news from Genor, Abogen, Bayer, Innovent.
Sino Biopharmaceuticals' subsidiary invoX Pharma acquired Nasdaq-listed biotech firm F-star Therapeutics for $161 million cash at $7.12 per share, as part of the effort to help the Chinese pharma giant dive deep in bispecifics in immunotherapy.
Beijing-based startup Helixon netted nearly RMB500 million ($74 million) in Series A round to lay the groundwork for AI drug discovery.
Beijing-based startup JD Biotech said it raised dozens of millions of yuan in Series Pre-A funding to advance its first CAR-NK cell therapy JDC06 into clinical trials. More news from Neurophth, Teligene, Zelgen.